Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125214681 | 12521468 | 1 | I | 201606 | 20160627 | 20160701 | 20160701 | EXP | US-BIOGEN-2016BI00258731 | BIOGEN | 51.95 | YR | M | Y | 0.00000 | 20160701 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125214681 | 12521468 | 1 | PS | TYSABRI | NATALIZUMAB | 1 | Unknown | U | 125104 | UNKNOWN | |||||||||
125214681 | 12521468 | 2 | SS | TYSABRI | NATALIZUMAB | 1 | Unknown | U | 125104 | UNKNOWN |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125214681 | 12521468 | 1 | Multiple sclerosis |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125214681 | 12521468 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125214681 | 12521468 | Body temperature decreased | |
125214681 | 12521468 | Kidney infection | |
125214681 | 12521468 | Urinary tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125214681 | 12521468 | 1 | 20071106 | 20141027 | 0 | |
125214681 | 12521468 | 2 | 20160413 | 20160511 | 0 |